emeis Société anonyme Valuation
Is ORPE.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ORPE.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ORPE.F ($6.6) is trading below our estimate of fair value ($89.63)
Significantly Below Fair Value: ORPE.F is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORPE.F?
Key metric: As ORPE.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is ORPE.F's PE Ratio? | |
|---|---|
| PE Ratio | 0.7x |
| Earnings | €1.47b |
| Market Cap | €983.57m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 27.9x |
| PEG Ratio | -0.006x |
Price to Earnings Ratio vs Peers
How does ORPE.F's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 38.3x | ||
USPH U.S. Physical Therapy | 96.3x | 29.4% | US$1.4b |
NHC National HealthCare | 15.4x | n/a | US$1.9b |
ARDT Ardent Health Partners | 26.4x | 38.3% | US$2.4b |
CON Concentra Group Holdings Parent | 15.3x | 4.0% | US$2.6b |
ORPE.F emeis Société anonyme | 0.7x | -108.0% | US$983.6m |
Price-To-Earnings vs Peers: ORPE.F is good value based on its Price-To-Earnings Ratio (0.7x) compared to the peer average (38.3x).
Price to Earnings Ratio vs Industry
How does ORPE.F's PE Ratio compare vs other companies in the US Healthcare Industry?
| 6 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 25.2x | 21.1% | |
ORPE.F emeis Société anonyme | 0.7x | -108.0% | US$1.04b |
THC Tenet Healthcare | 4.7x | -39.2% | US$14.77b |
NEUE NeueHealth | 1.5x | n/a | US$41.27m |
| 6 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 25.2x | 21.1% | |
ORPE.F emeis Société anonyme | 0.7x | -108.0% | US$1.04b |
Price-To-Earnings vs Industry: ORPE.F is good value based on its Price-To-Earnings Ratio (0.7x) compared to the US Healthcare industry average (25.1x).
Price to Earnings Ratio vs Fair Ratio
What is ORPE.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 0.7x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate ORPE.F's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | US$11.28 0% | 28.6% | US$15.01 | US$7.72 | n/a | 4 |
| Nov ’25 | US$6.60 | US$12.63 +91.4% | 23.0% | US$15.20 | US$8.58 | n/a | 3 |
| Oct ’25 | n/a | US$12,918.75 0% | 23.0% | US$15,546.92 | US$8,772.90 | n/a | 3 |
| Sep ’25 | n/a | US$12,591.55 0% | 23.0% | US$15,153.16 | US$8,550.71 | n/a | 3 |
| Aug ’25 | n/a | US$12,591.55 0% | 23.0% | US$15,153.16 | US$8,550.71 | n/a | 3 |
| Jul ’25 | n/a | US$12,758.43 0% | 24.7% | US$16,322.09 | US$8,596.30 | n/a | 4 |
| Jun ’25 | n/a | US$12,758.43 0% | 24.7% | US$16,322.09 | US$8,596.30 | n/a | 4 |
| May ’25 | n/a | US$11,710.41 0% | 20.7% | US$14,938.11 | US$8,429.36 | n/a | 4 |
| Apr ’25 | n/a | US$6,691.73 0% | 95.5% | US$15,037.59 | US$21.48 | n/a | 4 |
| Mar ’25 | n/a | US$3,921.99 0% | 123.9% | US$10,774.70 | US$21.55 | n/a | 3 |
| Feb ’25 | US$10.00 | US$2,977.16 +29,671.6% | 153.7% | US$10,875.48 | US$21.75 | n/a | 4 |
| Jan ’25 | US$0.001 | US$2,977.16 +297,716,050.1% | 153.7% | US$10,875.48 | US$21.75 | n/a | 4 |
| Dec ’24 | n/a | US$2,977.16 0% | 153.7% | US$10,875.48 | US$21.75 | n/a | 4 |
| Nov ’24 | n/a | US$4,117.09 0% | 117.1% | US$10,529.64 | US$21.06 | US$6.60 | 5 |
| Oct ’24 | n/a | US$4,129.69 0% | 117.1% | US$10,561.89 | US$21.12 | n/a | 5 |
| Sep ’24 | n/a | US$4,277.89 0% | 117.1% | US$10,940.92 | US$21.88 | n/a | 5 |
| Aug ’24 | US$1,920.00 | US$4,332.52 +125.7% | 115.6% | US$10,996.26 | US$33.01 | n/a | 5 |
| Jul ’24 | n/a | US$4,311.21 0% | 112.3% | US$10,761.95 | US$182.96 | n/a | 5 |
| Jun ’24 | n/a | US$5,317.92 0% | 93.5% | US$10,814.32 | US$183.85 | n/a | 4 |
| May ’24 | n/a | US$6,093.99 0% | 76.7% | US$10,956.50 | US$317.67 | n/a | 5 |
| Apr ’24 | n/a | US$5,960.47 0% | 69.5% | US$10,640.56 | US$308.51 | n/a | 6 |
| Mar ’24 | US$2,800.00 | US$11,741.52 +319.3% | 124.0% | US$46,132.39 | US$311.06 | n/a | 7 |
| Feb ’24 | US$6,200.00 | US$14,874.04 +139.9% | 91.1% | US$46,723.89 | US$4,346.41 | US$10.00 | 7 |
| Jan ’24 | US$5,850.00 | US$18,190.97 +211.0% | 86.5% | US$45,570.16 | US$4,239.08 | US$0.001 | 8 |
| Dec ’23 | US$6,300.00 | US$17,977.70 +185.4% | 84.1% | US$44,389.39 | US$5,987.37 | n/a | 8 |
| Nov ’23 | US$9,300.00 | US$26,140.30 +181.1% | 56.1% | US$43,351.14 | US$7,057.16 | n/a | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Lantheus Holdings
US$5.3b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$76.22
7D
-9.3%
1Y
10.3%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$56.05
7D
0.4%
1Y
-17.9%
Patterson Companies
US$1.7b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
PDCO
US$20.90
7D
-0.7%
1Y
-34.7%